STOCK TITAN
  1. Home
  2. News
  3. HALO

Halozyme Therapeutics Inc. - HALO STOCK NEWS

Welcome to our dedicated news page for Halozyme Therapeutics (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Halozyme Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Halozyme Therapeutics's position in the market.

News
Halozyme to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced Dr. Helen Torley, CEO, will present at upcoming investor conferences in March 2024. The events include TD Cowen 44th Annual Healthcare Conference, Leerink Partners Global Biopharma Conference, and Barclays 26th Annual Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
-
News
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
Rhea-AI Summary
Halozyme Therapeutics, Inc. (HALO) reports strong financial results for Q4 2023 and FY 2023, with total revenue of $829 million, a 26% YoY growth. The company reiterates 2024 financial guidance of $915-985 million in total revenue, a 10-19% YoY growth, and a new $750 million share repurchase program. Recent partner highlights include FDA acceptance for VYVGART Hytrulo and new drug applications by Takeda and Janssen. Financially, Q4 revenue increased by 27% YoY to $230 million, with GAAP diluted EPS of $0.65 and non-GAAP diluted EPS of $0.821.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.56%
Tags
earnings
-
News
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will release its Q4 and full year 2023 financial and operating results on February 20, 2024. A conference call will be held to discuss the results, and a live webcast and replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
conferences earnings
News
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that Takeda received European Commission approval for HYQVIA® co-formulated with Halozyme's ENHANZE® drug delivery technology as maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilization with intravenous immunoglobulin therapy. HYQVIA® also received FDA approval as maintenance therapy for adults with CIDP. The approval allows for the administration of HYQVIA® by a healthcare professional or self-administered in the patient's home after appropriate training. The centralized marketing authorization for HYQVIA® in CIDP is valid in all EU member states, Iceland, Liechtenstein, Norway, and Northern Ireland.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
none
-
News
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
Rhea-AI Summary
Halozyme Therapeutics, Inc. announced that argenx received approval from Japan's Ministry of Health, Labour and Welfare for VYVDURA® injection co-formulated with Halozyme's ENHANZE® drug delivery technology for the treatment of adult patients with generalized myasthenia gravis. The approval includes the option for patient self-administration at home. The approval is based on positive results from the Phase 3 ADAPT-SC study, demonstrating a reduction in total immunoglobulin G levels comparable to VYVGART® IV in adult gMG patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
-
News
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that Takeda received FDA approval for HYQVIA® co-formulated with Halozyme's ENHANZE® drug delivery technology for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. HYQVIA® is the only FDA-approved combination of immunoglobulin (IG) and hyaluronidase for subcutaneous immunoglobulin (SCIG) infusion. The treatment can be administered by a healthcare professional in various settings and can also be self-administered after training.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
fda approval
News
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that Roche received European Commission marketing authorization of Tecentriq® SC co-formulated with ENHANZE®, reducing treatment time by approximately 80% compared to standard intravenous infusion. The approval applies to all approved indications of Tecentriq® IV and represents the EU's first PD-(L)1 cancer immunotherapy for subcutaneous injection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
none
-
News
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host an Investor Business Forum and Long-Term Outlook Call on January 17, 2024, to provide detailed guidance on the revenue durability of its ENHANZE® drug delivery technology and present 2024 financial guidance as well as long-term financial outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
-
News
Halozyme to Present at Upcoming Investor Conferences
Rhea-AI Summary
Halozyme Therapeutics, Inc. (HALO) senior leadership team to present at Piper Sandler 35th Annual Healthcare Conference and 6th Annual Evercore ISI HealthCONx Conference. CFO Nicole LaBrosse and President/CEO Helen Torley to host investor meetings in New York and Miami, respectively, on November 29th, 2023. Live audio webcast and replays available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences
News
Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis
Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that argenx received European Commission approval for VYVGART® SC, a subcutaneous form of the drug for treating generalized myasthenia gravis in adult patients. This approval allows for patient self-administration, following the U.S. approval in June. VYVGART® SC is a combination of efgartigimod alfa and Halozyme's ENHANZE® drug delivery technology, approved based on positive results from the Phase 3 ADAPT-SC study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
Stock HALO logo
Halozyme Therapeutics Inc.

Nasdaq:HALO

HALO Rankings

#1202 Ranked by Market Cap
#3871 Ranked by Stock Gains
N/A Ranked by Dividends

HALO Stock Data

4.91B
125.47M
1.08%
100.28%
6.21%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About HALO

we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies